Reported 2 days ago
Jefferies has raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110 from $95 following the impressive launch of its COPD treatment Ohtuvayre, which saw first-quarter sales of $71 million, nearly a 90% increase. Analysts predict peak sales could reach $3 to $5 billion, with expectations of achieving $1 billion in sales by 2028 due to the strong market demand and safety profile of the product. Despite its potential, some investors see better opportunities in AI stocks.
Source: YAHOO